A follow-up study of these signature genes also identified a significantly lower gene expression level of SOCS2, NR4A2, and TNFAIP3 in MS patients with an aggressive disease course that correlated with expanded disability status scale (EDSS) change and relapse rate (9). Here, SOCS2 is linked to myeloid sarcoma.